[Characteristics of medical use of Korvazan® for restorative treatment of patients with myocardial infarction, counting the risk factors].
The largest contribution to mortality from cardiovascular diseases belongs risk factors for cardiovascular events. In order to determine the effectiveness of rehabilitation patients undergoing examined 240 patients with myocardial infarction with concomitant risk factors. The study found that the inclusion in the standard therapy of beta-blocker carvedilol in individually selected dose and depending on the risk factor of cardiovascular events helps increase myocardial functional reserves and increasing tolerance to physical exertion.
I P
IP
Vakaliuk
N B
NB
Tymochko
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol